HSK 26784
Alternative Names: HSK-26784Latest Information Update: 28 Jul 2024
At a glance
- Originator Haisco Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported B-cell lymphoma